8-KOther EventsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Corporate Update (Aug 25, 2014)

Filed August 25, 2014For Securities:ABT

Summary

Abbott Laboratories (ABT) has filed an 8-K report to announce the commencement of tender offers by its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, for the ordinary shares and American Depositary Shares (ADSs) of CFR Pharmaceuticals S.A. This filing details the launch of both a U.S. Offer targeting U.S. holders for ordinary shares and all holders for ADSs, and a simultaneous Chilean Offer for outstanding ordinary shares, aligning with Chilean tender offer regulations. The terms and pricing for both offers are consistent, with a slight variation for Chilean offer participants who can opt for payment in Chilean pesos. This strategic move indicates Abbott's intention to acquire CFR Pharmaceuticals, a company previously agreed upon in a transaction dated May 15, 2014. Investors should note this as a significant development in Abbott's growth strategy, potentially expanding its market presence and product portfolio, particularly within Latin America given CFR's operational base. The attached press release provides further details on the offer mechanics and timelines.

Key Highlights

  • 1Abbott Laboratories, through its subsidiary, has launched a tender offer for CFR Pharmaceuticals S.A.
  • 2The offer targets both ordinary shares (for U.S. holders) and American Depositary Shares (ADSs) of CFR Pharmaceuticals.
  • 3A separate Chilean Offer is being made simultaneously under Chilean regulations for CFR Pharmaceuticals ordinary shares.
  • 4Both the U.S. and Chilean offers are for 100% of the outstanding shares/ADSs, subject to the terms outlined in the offer documents.
  • 5The purchase price and general terms are consistent across both offers, with Chilean offer participants having an option for payment in Chilean pesos.
  • 6This action is pursuant to a Transaction Agreement signed on May 15, 2014, as previously reported.
  • 7The filing includes a press release dated August 25, 2014, announcing the launch of these tender offers.

Frequently Asked Questions

This 8-K filing formally announces the commencement of tender offers by Abbott Laboratories' subsidiary to acquire CFR Pharmaceuticals S.A. This action is a key step in Abbott's previously announced agreement to acquire CFR Pharmaceuticals.

Abbott Laboratories, through its subsidiary Abbott Laboratories (Chile) Holdco (Dos) SpA, is making offers to acquire the ordinary shares and American Depositary Shares (ADSs) of CFR Pharmaceuticals S.A.

Yes, there is a U.S. Offer primarily for U.S. holders of ordinary shares and all holders of ADSs, and a simultaneous Chilean Offer made under Chilean regulations for ordinary shares. Both offers aim to acquire 100% of the respective securities.

While this filing details the commencement of the offer, it does not disclose the specific financial terms or price per share/ADS. Investors will need to refer to the referenced 'U.S. Offer to Purchase' and related documents for details on the offer price and the total potential cost of the acquisition. This move signifies an investment and potential expansion for Abbott Laboratories.